Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma

PRIMARY OBJECTIVES:

I. Determine the 18 month progression free survival (PFS) for each arm of therapy stratified
by positron emission tomography (PET)/computed tomography (CT)-2 response.

SECONDARY OBJECTIVES:

I. Assess safety, tolerability, and quality of life (QOL) for each arm of therapy.

II. Measure PET/CT-2 negativity rate after 2 lead-in cycles of doxorubicin, bleomycin,
vinblastine, dacarbazine (ABVD).

III. Evaluate the 3-year PFS and overall survival (OS) for each arm of treatment.

EXPLORATORY OBJECTIVES:

I. Evaluate if a baseline antitumor immune response, as assessed by a Nanostring gene panel,
correlates with PFS.

II. Evaluate if minimal residual disease (MRD) status, as monitored by cancer personalized
profiling by deep sequencing (CAPP-Seq) of circulating tumor (ct) deoxyribonucleic acid
(DNA), can be correlated with PFS.

OUTLINE: Participants are assigned to 1 of 2 groups based on their PET/CT-2 scans.

GROUP I (PET/CT-2 NEGATIVE): Participants without bulky disease are randomized to either Arm
A or B and participants with bulky disease are assigned to Arm B.

ARM A: Participants receive brentuximab vedotin intravenously (IV) over 30 minutes and
nivolumab IV over 60 minutes on day 1. Treatment repeat every 21 days for up to 3 courses in
the absence of disease progression or unacceptable toxicity.

ARM B: Participants receive doxorubicin IV, bleomycin IV, vinblastine IV, dacarbazine IV on
days 1 and 15. Treatment repeats every 28 days for up to 2 courses in the absence of disease
progression or unacceptable toxicity. Participants then receive nivolumab IV over 60 minutes
on day 1. Treatment with nivolumab repeats every 14 days for up to 6 courses in the absence
of disease progression or unacceptable toxicity.

GROUP II (PET/CT-2 POSITIVE): Participants receive doxorubicin IV, vinblastine IV,
dacarbazine, IV and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment
repeats every 28 days for up to 4 courses in the absence of disease progression or
unacceptable toxicity. Participants that are PET/CT negative receive nivolumab IV over 60
minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 courses in the
absence of disease progression or unacceptable toxicity.

After completion of study treatment, participants are followed up for 3 years.

Inclusion Criteria:

- Documented informed consent of the participant and/or legally authorized
representative.

- Assent, when appropriate, will be obtained per institutional guidelines.

- Eastern Cooperative Oncology Group (ECOG) =< 2.

- Histologically confirmed diagnosis of classical Hodgkin lymphoma (cHL) by current
World Health Organization classification (nodular sclerosis, mixed cellularity,
lymphocyte rich, lymphocyte depleted, or classical Hodgkin lymphoma, NOS [not
otherwise specified]) at local enrolling center.

- Stage IA, IB, IIA, or IIB cHL by Cotswold modified Ann Arbor staging done prior to any
treatment with ABVD.

- Ability to document transverse diameter in cm of largest mediastinal mass and
favorable versus unfavorable risk factor criteria as determined by German Hodgkin
Study Group (GHSG) criteria at baseline prior to ABVD treatment.

- Must have at baseline prior to ABVD treatment at least one lesion that is > 1.5 cm in
the longest diameter on cross-sectional imaging and measureable in two perpendicular
dimensions on CT and fludeoxyglucose (FDG) avid by PET.

- Absolute neutrophil count (ANC) >= 1,000/mm^3.

- Platelets >= 75,000/mm^3.

- Hemoglobin >= 8 g/dL.

- Total bilirubin =< 1.5 X upper limit of normal (ULN) (unless the elevation is known to
be related to Gilbert's syndrome).

- Aspartate aminotransferase (AST) =< 2.5 x ULN.

- Alanine aminotransferase (ALT) =< 2.5 x ULN.

- Creatinine clearance >= 30 mL/min per 24 hour urine collection or the Cockcroft-Gault
formula.

- Left ventricular ejection fraction (LVEF) >= 45%.

- Carbon monoxide diffusion capacity (DLCO) (adjusted for hemoglobin [Hb]) >= 60%.

- Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If
the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
will be required.

- Agreement by females and males of childbearing potential to use an effective method of
birth control or abstain from heterosexual activity for the course of the study
through at least 6 months after the last dose of protocol therapy.

- Childbearing potential defined as not being surgically sterilized (men and women)
or have not been free from menses for > 1 year (women only).

Exclusion Criteria:

- Patients must be naive in terms of any prior therapy for Hodgkin lymphoma (including
immunotherapy, chemotherapy or radiation therapy) with the exception that they may
have received up to 2 cycles of ABVD as standard of care therapy prior to enrollment,
as long as they can start subsequent therapy (therapy administered in Arms A, B1/B2,
or C) within timelines specified by the trial.

- Subjects with a non-lymphoma related condition requiring systemic treatment with
either corticosteroids (> 10 mg daily prednisone equivalents) or other
immunosuppressive medications within 14 days of study drugs administration. Patients
can have received short term dosing of steroids prior to the start of ABVD
chemotherapy for management of symptoms of cHL and any steroids given for cHL symptom
management should be tapered down to 10 mg or less of prednisone equivalents by the
time of start of ABVD chemotherapy, and fully tapered off by week 1 of ABVD.

- Sensory > grade 1 or any peripheral motor neuropathy.

- History of another primary malignancy that has not been in remission for at least 3
years. (The following are exempt from the 3-year limit: nonmelanoma skin cancer, fully
excised melanoma in situ [Stage 0], curatively treated localized prostate cancer, and
cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on
Papanicolaou [PAP] smear)

- Known cerebral/meningeal disease.

- History of progressive multifocal leukoencephalopathy (PML).

- Known history of pancreatitis.

- Documented history of a cerebral vascular event (stroke or transient ischemic attack),
unstable angina, myocardial infarction, or cardiac symptoms consistent with New York
Heart Association class III-IV within 6 months prior to their first dose of study
drug(s).

- Uncontrolled cardiac disease including ventricular dysfunction, left ventricular
ejection fraction < 45%, coronary artery disease, or arrhythmias.

- Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient
contained in the drug formulation of brentuximab vedotin, nivolumab, or any component
of ABVD.

- Known active infection with hepatitis B or hepatitis C. Patients who are hepatitis B
carriers can enroll if have a negative hepatitis B polymerase chain reaction (PCR) DNA
test and are on hepatitis B suppressive medication management with entecavir or
lamivudine. Patients with past active hepatitis C virus (HCV) infection are eligible
if they are PCR negative after curative therapy. Testing to be done only in patients
suspected of having infections or exposures.

- Known active infection with human immunodeficiency virus (HIV). Patients who are HIV
positive can enroll if CD4 count is > 200/uL and have an undetectable HIV viral load
within 28 days of enrollment, have concurrent management with infectious disease
specialists, and are on stable combination antiretroviral therapy. Participants are
required to be on antiretroviral regimens that are in accordance with the current
International acquired immune deficiency syndrome (AIDS) Society guidelines
concurrently with chemotherapy. The specific agents are at the discretion of the
Investigator and the use of investigational agents currently available on an expanded
access basis is allowed. Use of experimental antiretroviral agents or those containing
zidovudine (including Combivir and Trizivir) or ritonavir (includes Norvir or
Kaletra), Cobicistat, Didanosine (Videx or Videx EC), or similar potent CYP3
inhibitors are prohibited. In order to be eligible, participants taking zidovudine or
ritonavir, Cobicistat, Didanosine, or other CYP3 inhibitors must change to a different
regimen 7 days prior to therapy initiation. Changes to highly active antiretroviral
therapy (HAART) therapy during the study may be made if medically necessary (toxicity,
failure of regimen, etc.). Participants must be on HAART for at least 7 days prior to
therapy.

- Any active systemic viral, bacterial, or fungal infection requiring treatment with IV
antimicrobial therapy within 1 week prior to enrollment.

- Subjects with active interstitial pneumonitis.

- Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,
type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only
requiring hormone replacement, psoriasis not requiring systemic treatment, or
conditions not expected to recur in the absence of an external trigger are permitted
to enroll.

- Females only: pregnant or breastfeeding.

- Any other condition that would, in the investigator's judgment, contraindicate the
patient's participation in the clinical study due to safety concerns with clinical
study procedures.

- Prospective participants who, in the opinion of the investigator, may not be able to
comply with all study procedures (including compliance issues related to
feasibility/logistics).